JP2024536341A5 - - Google Patents
Info
- Publication number
- JP2024536341A5 JP2024536341A5 JP2024520543A JP2024520543A JP2024536341A5 JP 2024536341 A5 JP2024536341 A5 JP 2024536341A5 JP 2024520543 A JP2024520543 A JP 2024520543A JP 2024520543 A JP2024520543 A JP 2024520543A JP 2024536341 A5 JP2024536341 A5 JP 2024536341A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- ticagrelor
- acid
- smedds
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163251935P | 2021-10-04 | 2021-10-04 | |
| US63/251,935 | 2021-10-04 | ||
| PCT/IB2022/059429 WO2023057879A1 (en) | 2021-10-04 | 2022-10-03 | Methods and products for treating subjects with autism spectrum disorders |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024536341A JP2024536341A (ja) | 2024-10-04 |
| JP2024536341A5 true JP2024536341A5 (cg-RX-API-DMAC10.html) | 2025-01-14 |
Family
ID=83688729
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024520543A Pending JP2024536341A (ja) | 2021-10-04 | 2022-10-03 | 自閉症スペクトラム障害を有する対象を治療するための方法及び製品 |
Country Status (16)
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025051399A1 (en) * | 2023-09-10 | 2025-03-13 | Dafechem Ltd | Liquid ticagrelor formulation |
| WO2025247961A1 (en) * | 2024-05-31 | 2025-12-04 | Centre Hospitalier Universitaire Vaudois (C.H.U.V.) | Lpa-lpar signaling as a therapeutic target or diagnostic tool for brain diseases |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9233966B2 (en) * | 2012-04-05 | 2016-01-12 | Dr. Reddy's Laboratories Limited | Preparation of ticagrelor |
| CN104971042B (zh) | 2014-04-04 | 2018-01-05 | 中国医学科学院医药生物技术研究所 | 替格瑞洛口服自微乳组合物 |
| CN104434931A (zh) * | 2014-11-06 | 2015-03-25 | 南京华威医药科技开发有限公司 | 含替格瑞洛和阿司匹林的复方口服固体剂及其制备方法 |
| CN105669674A (zh) * | 2014-11-21 | 2016-06-15 | 重庆圣华曦药业股份有限公司 | 一种替卡格雷新晶型及其在药物制剂中的应用 |
| RS66536B1 (sr) * | 2016-04-21 | 2025-03-31 | Astrazeneca Ab | Tablete za oralno raspadanje |
| CN105943515A (zh) * | 2016-06-24 | 2016-09-21 | 山东鲁抗医药股份有限公司 | 一种替格瑞洛口腔崩解片及其制备方法 |
| CN108078944A (zh) * | 2016-11-22 | 2018-05-29 | 重庆植恩药业有限公司 | 含有替格瑞洛的固体组合物及其制备方法 |
| TR201617983A2 (tr) * | 2016-12-07 | 2018-06-21 | Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi | Ti̇cagrelorun kati oral farmasöti̇k bi̇leşi̇mleri̇ |
| US10614684B2 (en) * | 2017-01-31 | 2020-04-07 | The United States Government As Represented By The | Treatment of kidney diseases associated with elevated AVP |
| EP3700525A4 (en) * | 2017-10-27 | 2021-08-25 | Beyond Barriers Therapeutics, Inc. | IMPROVED PROVISION OF ANTIOXIDANTS FOR TREATMENT OF CENTRAL NERVOUS SYSTEM DISEASES WITH OXIDATIVE STRESS |
| KR102007731B1 (ko) * | 2018-02-12 | 2019-08-06 | 충남대학교산학협력단 | 티카그렐러를 포함하는 자가 미세유화 약물전달시스템 조성물 및 이의 제조방법 |
| CN110876750A (zh) * | 2018-09-06 | 2020-03-13 | 江苏恒瑞医药股份有限公司 | 一种含有替格瑞洛或其可药用盐的缓释组合物 |
| CA3179635A1 (en) * | 2020-05-29 | 2021-12-02 | Boulder Bioscience Llc | Methods for improved endovascular thrombectomy using 3,3'-diindolylmethane |
-
2022
- 2022-10-03 IL IL311681A patent/IL311681B2/en unknown
- 2022-10-03 CN CN202280072869.XA patent/CN118265521A/zh active Pending
- 2022-10-03 EP EP22786511.0A patent/EP4412616A1/en active Pending
- 2022-10-03 PE PE2024000669A patent/PE20241338A1/es unknown
- 2022-10-03 AU AU2022358998A patent/AU2022358998B2/en active Active
- 2022-10-03 TW TW111137520A patent/TW202322821A/zh unknown
- 2022-10-03 WO PCT/IB2022/059429 patent/WO2023057879A1/en not_active Ceased
- 2022-10-03 KR KR1020247015045A patent/KR20240089377A/ko active Pending
- 2022-10-03 JP JP2024520543A patent/JP2024536341A/ja active Pending
- 2022-10-03 CA CA3232273A patent/CA3232273A1/en active Pending
- 2022-10-03 CR CR20240184A patent/CR20240184A/es unknown
- 2022-10-03 US US17/937,525 patent/US11878016B2/en active Active
- 2022-10-03 MX MX2024004150A patent/MX2024004150A/es unknown
-
2024
- 2024-04-03 CL CL2024000992A patent/CL2024000992A1/es unknown
- 2024-05-02 EC ECSENADI202433949A patent/ECSP24033949A/es unknown
- 2024-05-02 CO CONC2024/0005762A patent/CO2024005762A2/es unknown
-
2025
- 2025-10-03 AU AU2025242229A patent/AU2025242229A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR102299359B1 (ko) | 케타민 경피 전달 시스템 | |
| EP2081547B1 (fr) | Forme galenique pour l'administration par voie trans-muqueuse de principes actifs | |
| CN103889508B (zh) | 用于传递丁丙诺啡的防滥用性粘膜粘附剂装置 | |
| JP2013501718A5 (cg-RX-API-DMAC10.html) | ||
| US12128027B2 (en) | N—N-dimethyltryptamine (DMT) and DMT analog compositions, methods of making, and methods of use thereof | |
| EP3043777A1 (en) | Sublingual buprenorphine spray | |
| JP2010518086A (ja) | スフェンタニルおよびナロキソンを含む経口腔投与製剤 | |
| WO2020086673A1 (en) | Ketamine oral transmucosal delivery system | |
| CN101068571A (zh) | 改善透粘膜给药制剂的吸收的方法 | |
| JP2025509390A5 (cg-RX-API-DMAC10.html) | ||
| JP2018513869A5 (cg-RX-API-DMAC10.html) | ||
| CA3127926A1 (en) | Methods of treating parkinson's disease by administration of apomorphine to an oral mucosa | |
| IL311681B1 (en) | Methods and products for treating people with autism spectrum disorders | |
| KR20230106658A (ko) | 구강용 박막 | |
| ZA200706640B (en) | Method for a treatment with a medicament combination and medicament combinations suitable for the same | |
| AU2024356340A1 (en) | N-n-dimethyltryptamine (dmt) and dmt analog oral transmucosal film compositions, methods of making, and methods of use thereof | |
| US20120220557A1 (en) | Liquid propellant-free formulation comprising an antimuscarinic drug | |
| US20250319019A1 (en) | Buccomucoadhesive patch-based drug delivery system for tacrolimus | |
| CN104394865B (zh) | 稳定性提高的包含氨氯地平和氯沙坦的组合物 | |
| JP2020073583A (ja) | ミューオピオイド受容体アンタゴニストとオピオイド剤との組み合わせ剤形 | |
| CN115569115A (zh) | 一种同时包载全氟化碳和二甲双胍的脂质纳米制剂及其制备方法与应用 | |
| AU2009257385A1 (en) | Pharmaceutical formulation of ketorolac for intranasal administration | |
| JP4807974B2 (ja) | 経皮吸収促進組成物 | |
| JPH0788300B2 (ja) | エピニンあるいはその製薬的に許容しうる塩を含む医薬組成物ならびに用途 | |
| FR2845916A1 (fr) | Composition pharmaceutique associant le tenatoprazole et un antagoniste des recepteurs h2 a l'histamine |